{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T08:56:16Z","timestamp":1781254576468,"version":"3.54.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clml.2026.03.006","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T16:02:11Z","timestamp":1773676931000},"page":"e767-e773","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mapping the Landscape of Quality of Life in Smoldering Multiple Myeloma Clinical Trials: A Systematic Review"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5630-6856","authenticated-orcid":false,"given":"Jos\u00e9 Emiliano","family":"Montelongo-Cepeda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sof\u00eda I.","family":"Quezada-Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector A.","family":"Vaquera Alfaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra De Las","family":"Fuentes-Cepeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yadith Karina","family":"Lopez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perla R.","family":"Colunga-Pedraza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth K.","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0460-6427","authenticated-orcid":false,"given":"David","family":"G\u00f3mez-Almaguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.clml.2026.03.006_bib0001","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.clml.2026.03.006_bib0002","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41591-022-02183-6","article-title":"Prevalence of smoldering multiple myeloma based on nationwide screening","volume":"29","author":"Thorsteinsd\u00f3ttir","year":"2023","journal-title":"Nat Med"},{"issue":"25","key":"10.1016\/j.clml.2026.03.006_bib0003","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (Asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.clml.2026.03.006_bib0004","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","article-title":"International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)","volume":"10","author":"Mateos","year":"2020","journal-title":"Blood Cancer J"},{"issue":"18","key":"10.1016\/j.clml.2026.03.006_bib0005","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1056\/NEJMoa2409029","article-title":"Daratumumab or active monitoring for high-risk smoldering multiple myeloma","volume":"392","author":"Dimopoulos","year":"2025","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clml.2026.03.006_bib0006","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41408-022-00719-0","article-title":"Smoldering multiple myeloma current treatment algorithms","volume":"12","author":"Rajkumar","year":"2022","journal-title":"Blood Cancer J"},{"issue":"9","key":"10.1016\/j.clml.2026.03.006_bib0007","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.clml.2025.03.008","article-title":"Expert perspectives on current challenges and emerging approaches for Multiple myeloma: narrative review of an inaugural bridging the gaps in leukemia, lymphoma, and multiple myeloma","volume":"25","author":"Chari","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.clml.2026.03.006_bib0008","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13045-025-01711-4","article-title":"Practice-changing updates on multiple myeloma: highlights from the 2024 ASH annual meeting","volume":"18","author":"Ntanasis-Stathopoulos","year":"2025","journal-title":"J Hematol OncolJ Hematol Oncol."},{"key":"10.1016\/j.clml.2026.03.006_bib0009","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1394048","article-title":"Bispecific antibodies for the treatment of relapsed\/refractory multiple myeloma: updates and future perspectives","volume":"14","author":"Parrondo","year":"2024","journal-title":"Front Oncol"},{"issue":"21","key":"10.1016\/j.clml.2026.03.006_bib0010","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1182\/bloodadvances.2018021220","article-title":"Timing of treatment of smoldering myeloma: early treatment","volume":"2","author":"Mateos","year":"2018","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.clml.2026.03.006_bib0011","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1634\/theoncologist.2015-0303","article-title":"The changing landscape of smoldering multiple myeloma: a European perspective","volume":"21","author":"Caers","year":"2016","journal-title":"The Oncologist"},{"issue":"9","key":"10.1016\/j.clml.2026.03.006_bib0012","doi-asserted-by":"crossref","first-page":"oyaf216","DOI":"10.1093\/oncolo\/oyaf216","article-title":"Contextualizing results of randomized trials in smoldering myeloma","volume":"30","author":"Mohyuddin","year":"2025","journal-title":"The Oncologist"},{"issue":"8","key":"10.1016\/j.clml.2026.03.006_bib0013","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1182\/bloodadvances.2024015575","article-title":"Distress and symptom burden in patients with monoclonal gammopathy of undetermined significance and smoldering myeloma","volume":"9","author":"O\u2019Donnell","year":"2025","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.03.006_bib0014","doi-asserted-by":"crossref","first-page":"4775","DOI":"10.1182\/blood-2023-190035","article-title":"Understanding patient preferences for intervention in individuals with precursor multiple myeloma: the preference study","volume":"142","author":"Marinac","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.03.006_bib0015","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1182\/blood-2024-209726","article-title":"The complex psychological effects and perspectives of patients on diagnosis, monitoring, and future treatments for MGUS and smoldering myeloma: a mixed methods study","volume":"144","author":"Quinn","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.03.006_bib0016","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.clml.2026.03.006_bib0017","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1200\/JCO.19.01740","article-title":"Randomized trial of lenalidomide versus observation in smoldering multiple myeloma","volume":"38","author":"Lonial","year":"2020","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.clml.2026.03.006_bib0018","doi-asserted-by":"crossref","first-page":"8046","DOI":"10.1200\/JCO.2023.41.16_suppl.8046","article-title":"ISAMAR: multicenter phase II single arm trial of isatuximab (ISA) with\/without lenalidomide (LEN) in pts with high risk smoldering multiple myeloma (HRSMM)","volume":"41","author":"Manasanch","year":"2023","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.03.006_bib0019","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1182\/blood-2024-210335","article-title":"Iberdomide alone or in combination with Dexamethasone for the treatment of intermediate- or high-risk smoldering multiple myeloma (SMM)","volume":"144","author":"Joseph","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2026.03.006_bib0020","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s41687-020-00253-2","article-title":"Symptom burden and health-related quality of life impacts of smoldering multiple myeloma: the patient perspective","volume":"4","author":"Jean-Baptiste","year":"2020","journal-title":"J Patient-Rep Outcomes"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.03.006_bib0021","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1182\/blood-2023-186397","article-title":"The early benefits and psychological effects of screening for monoclonal gammopathy of undetermined significance: results of the Istopmm study","volume":"142","author":"R\u00f6gnvaldsson","year":"2023","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2026.03.006_bib0022","doi-asserted-by":"crossref","first-page":"e1145","DOI":"10.1016\/j.clml.2025.09.016","article-title":"The unmet psychological needs of people living with multiple myeloma and smouldering myeloma: a review of current approaches and future directions","volume":"25","author":"Tuckey","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.1016\/j.clml.2026.03.006_bib0023","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41408-019-0172-1","article-title":"Patients with precursor disease exhibit similar psychological distress and mental HRQOL as patients with active myeloma","volume":"9","author":"Maatouk","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2026.03.006_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.575168","article-title":"Real world experience of Daratumumab: evaluating lymphopenia and adverse events in multiple myeloma patients","volume":"10","author":"Cottini","year":"2021","journal-title":"Front Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.03.006_bib0025","doi-asserted-by":"crossref","first-page":"6640","DOI":"10.1182\/blood-2023-184914","article-title":"The impact of continuous lenalidomide maintenance treatment on people living with multiple myeloma - a single-centre qualitative service evaluation","volume":"142","author":"Buck","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2026.03.006_bib0026","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2025.2560679","article-title":"Efficacy and toxicity of treatment of smoldering multiple myeloma: a systematic review and meta-analysis","volume":"57","author":"Quan","year":"2025","journal-title":"Ann Med"},{"issue":"1","key":"10.1016\/j.clml.2026.03.006_bib0027","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41408-025-01312-x","article-title":"Observation or treatment for smoldering multiple myeloma? A systematic review and meta-analysis of randomized controlled studies","volume":"15","author":"Ntanasis-Stathopoulos","year":"2025","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.clml.2026.03.006_bib0028","doi-asserted-by":"crossref","first-page":"54","DOI":"10.46989\/001c.123608","article-title":"Psychological impact in individuals with monoclonal gammopathy of undetermined significance and smoldering multiple myeloma","volume":"6","author":"Patel","year":"2024","journal-title":"Clin Hematol Int"},{"issue":"1","key":"10.1016\/j.clml.2026.03.006_bib0029","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/bjh.70245","article-title":"SECURE study: incidentally detected MGUS patients have comparable depression and anxiety rates to UK general population","volume":"208","author":"Knight","year":"2026","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2026.03.006_bib0030","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13063-015-1105-3","article-title":"Patients\u2019 willingness to participate in clinical trials and their views on aspects of cancer research: results of a prospective patient survey","volume":"17","author":"Moorcraft","year":"2016","journal-title":"Trials"},{"issue":"6","key":"10.1016\/j.clml.2026.03.006_bib0031","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/sj.bjc.6602423","article-title":"Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy","volume":"92","author":"Nurgat","year":"2005","journal-title":"Br J Cancer"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.03.006_bib0032","doi-asserted-by":"crossref","first-page":"6924","DOI":"10.1182\/blood-2024-203731","article-title":"Spotlight: smoldering Myeloma high-risk patient observation and longitudinal insight trial","volume":"144","author":"Nuli","year":"2024","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026000704?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026000704?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T08:05:24Z","timestamp":1781251524000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026000704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2152265026000704"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.03.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mapping the Landscape of Quality of Life in Smoldering Multiple Myeloma Clinical Trials: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}